BDSI Closes Public Offering of 4.4 Million Shares
05 Outubro 2005 - 12:13PM
Business Wire
BioDelivery Sciences International, Inc. (NASDAQ:BDSI, BDSIW), a
specialty pharmaceutical company, announced today that it has
consummated its public offering of 4,400,000 shares of common
stock, resulting in gross proceeds of $8,800,000 million to the
company. The public price per share for the offering was $2.00. The
offering was underwritten by Ferris, Baker Watts Incorporated,
Maxim Group LLC and GunnAllen Financial, Inc. The underwriters have
been granted an option to purchase up to an additional 660,000
shares of common stock from BDSI to cover over-allotments. If the
over allotment option is exercised, of which no assurance can be
given, the additional shares will also be sold at $2.00 per share
and will result in additional gross proceeds to BDSI of up to
$1,320,000. This communication shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any
sale of any securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful. BioDelivery Sciences
International, Inc. is a specialty biopharmaceutical company that
is exploiting its licensed and patented drug delivery technologies
to develop and commercialize, either on its own or in partnerships
with third parties, clinically-significant new formulations of
proven therapeutics targeted at "acute" treatment opportunities
such as pain, anxiety, nausea and vomiting and infections. The
company's drug delivery technologies include: (i) the patented
Bioral(R) nanocochleate technology, designed for a potentially
broad base of applications, and (ii) the patented BEMA(TM)
(transmucosal or mouth) drug delivery technology. The company's
headquarters are located in Morrisville, North Carolina and its
principal laboratory is located in Newark, New Jersey. Note: Except
for the historical information contained herein, this press release
contains, among other things, certain forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act
of 1995, that involve risks and uncertainties. Such statement may
include, without limitation, statements with respect to the
Company's plans, objectives, expectations and intentions and other
statements identified by words such as "may", "could", "would",
"should", "believes", "expects", "anticipates", "estimates",
"intends", "plans" or similar expressions. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the
Securities and Exchange Commission. Actual results may differ from
those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). L.G. Zangani, LLC provides
financial public relations service to the Company. As such L.G.
Zangani, LLC and/or its officers, agents and employees, receives
remuneration for public relations and or other services in the form
of monies, capital stock in the Company, warrants or options to
purchase capital in the Company.
Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024